Michael Schomaker
Michael Schomaker
Home
Research
Software & Code
Teaching
Book
Contact
Light
Dark
Automatic
HIV
Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy
Anti-V3-Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2-Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency
Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies
Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis
CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South Africa
Immune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South Africa
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype
Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa
Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa
«
»
Cite
×